Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M36.7Revenue $M21.0Net Margin (%)-44.1Altman Z-Score-5.7
Enterprise Value $M-0.0EPS $-0.1Operating Margin %-44.9Piotroski F-Score6
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-44.1Higher ROA y-yY
Price/Book0.810-y EBITDA Growth Rate %-20.3Quick Ratio10.7Cash flow > EarningsY
Price/Sales1.85-y EBITDA Growth Rate %-14.6Current Ratio10.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-17.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-19.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M91.9ROIC % (ttm)-110.4Gross Margin Increase y-yY

Gurus Latest Trades with VICL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VICLJohn Rogers 2015-12-31 Reduce$0.35 - $0.53
($0.41)
$ 0.40-2%Reduce -6.51%6,952,175
VICLJohn Rogers 2015-09-30 Reduce$0.46 - $0.7
($0.61)
$ 0.40-34%Reduce -0.32%7,436,270
VICLJohn Rogers 2015-06-30 Add$0.7 - $1.48
($0.99)
$ 0.40-60%Add 7.21%7,460,515
VICLJohn Rogers 2015-03-31 Add$0.86 - $1.17
($1.02)
$ 0.40-61%Add 7.34%6,958,945
VICLGeorge Soros 2014-09-30 Sold Out $1.12 - $1.31
($1.24)
$ 0.40-68%Sold Out0
VICLGeorge Soros 2014-06-30 Buy $1.12 - $1.35
($1.19)
$ 0.40-66%New holding58,179
VICLJohn Rogers 2013-12-31 Add0.03%$1.015 - $1.49
($1.2)
$ 0.40-67%Add 39.31%7,062,104
VICLJohn Rogers 2013-06-30 Add0.13%$2.93 - $4.22
($3.52)
$ 0.40-89%Add 93.26%5,134,817
VICLJohn Rogers 2013-03-31 Add0.08%$2.91 - $4.26
($3.54)
$ 0.40-89%Add 71.60%2,656,967
VICLJohn Rogers 2012-12-31 Add0.03%$2.74 - $4.32
($3.31)
$ 0.40-88%Add 49.50%1,548,357
VICLJohn Rogers 2012-03-31 Add0.01%$3.02 - $4.28
($3.23)
$ 0.40-88%Add 26.34%877,193
VICLJohn Rogers 2011-06-30 Reduce-0.01%$2.88 - $4.81
($3.75)
$ 0.40-89%Reduce -30.97%577,773
VICLJohn Rogers 2010-09-30 Add0.03%$2.21 - $3.86
($3.2)
$ 0.40-88%Add 548.18%795,728
VICLJohn Rogers 2009-06-30 Buy 0.01%$1.95 - $2.76
($2.28)
$ 0.40-82%New holding137,198
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VICL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VICL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2016-03-15Sell8,750$0.41-2.44view
SAMANT VIJAY BPresident & CEO 2016-03-03Sell37,500$0.3611.11view
Ramos Anthony AlanVP, Chief Accounting Officer 2016-02-19Sell7,500$0.3321.21view
Ramos Anthony AlanVP, Chief Accounting Officer 2016-01-25Sell193$0.3514.29view
SAMANT VIJAY BPresident & CEO 2016-01-12Sell59,737$0.3514.29view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2016-01-11Sell974$0.3611.11view
SAMANT VIJAY BPresident & CEO 2016-01-07Sell75,000$0.3611.11view
Ramos Anthony AlanVP, Chief Accounting Officer 2015-10-23Sell193$0.392.56view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2015-10-12Sell974$0.43-6.98view
SAMANT VIJAY BPresident & CEO 2015-10-12Sell4,738$0.41-2.44view

Quarterly/Annual Reports about VICL:

News about VICL:

Articles On GuruFocus.com
CEOs Sell Vical, PhotoMedex, E.W. Scripps, Smart & Final Stores Jan 18 2016 
Red Hat (RHT) and Five Below (FIVE) Strong Performance Metrics; Vical (VICL) Targets Multi-billion S Mar 26 2015 
John Rogers Comments on Vical Feb 26 2014 
Kids Decide on Dolls or Devices - JAKK, Others 70% Off Sep 17 2013 
Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI Jan 21 2013 
Vical Inc. Insiders Boost Shares after Company’s NASDAQ Listing Gets Upgrade Jan 17 2013 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Vical Inc. (VICL) CEO Vijay B Samant buys 1,000 Shares Jan 20 2011 
Vical Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vical Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Vical Announces News Release and Conference Call Schedule for First Quarter 2016 Financial Results May 02 2016
Vical Announces News Release and Conference Call Schedule for First Quarter 2016 Financial Results May 02 2016
FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis Mar 30 2016
FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis Mar 30 2016
VICAL INC Financials Mar 18 2016
Vical, Inc. :VICL-US: Earnings Analysis: 2015 By the Numbers Mar 17 2016
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 14 2016
Q4 2015 Vical Inc Earnings Release - Before Market Open Mar 14 2016
Vical reports 4Q loss Mar 14 2016
Vical reports 4Q loss Mar 14 2016
Vical Reports Fourth Quarter 2015 Financial Results Mar 14 2016
Investor Calendar Invites You to the Vical Fourth Quarter and Fiscal Year 2015 Earnings Webcast Live... Mar 11 2016
Vical to Present at the 28th Annual ROTH Conference Mar 09 2016
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2015 Financial Results Mar 07 2016
Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397 Mar 07 2016
VICAL INC Files SEC form 8-K, Other Events Feb 04 2016
CEOs Sell Vical, PhotoMedex, E.W. Scripps, Smart & Final Stores Jan 18 2016
Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis Jan 07 2016
FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis Jan 06 2016
Vical Appoints Dr. Thomas Shenk to Board of Directors Dec 21 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)